Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer
Introduction: Non-small cell lung cancer (NSCLC) was the primary cause of death in lung cancer. Tyrosine kinase inhibitors (TKIs) were one of the management options for NSCLC. Meanwhile, serum carcinoembryonic antigen (CEA) plays a crucial role in the diagnosis and prognosis of NSCLC patients. This...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Airlangga
2025-05-01
|
| Series: | Jurnal Respirasi |
| Subjects: | |
| Online Access: | https://e-journal.unair.ac.id/JR/article/view/68755 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467973926912000 |
|---|---|
| author | Agus Andreas Santoso Suryanti Dwi Pratiwi Yani Jane Sugiri Harun Al Rasyid Aditya Sri Listyoko |
| author_facet | Agus Andreas Santoso Suryanti Dwi Pratiwi Yani Jane Sugiri Harun Al Rasyid Aditya Sri Listyoko |
| author_sort | Agus Andreas Santoso |
| collection | DOAJ |
| description | Introduction: Non-small cell lung cancer (NSCLC) was the primary cause of death in lung cancer. Tyrosine kinase inhibitors (TKIs) were one of the management options for NSCLC. Meanwhile, serum carcinoembryonic antigen (CEA) plays a crucial role in the diagnosis and prognosis of NSCLC patients. This study aimed to determine the effectiveness of epidermal growth factor receptor (EGFR)-TKI based on progression-free survival (PFS) and overall survival (OS) in NSCLC patients with common EGFR mutations.
Methods: This retrospective cohort study used a total sampling method. The serum CEA level was measured before the initial treatment. Tyrosine kinase inhibitors therapy was monitored with PFS and OS. Statistical analysis for comparing prognosis in NSCLC among TKI groups used Kruskal-Wallis, analysis of variance (ANOVA), Mann-Whitney, and Spearman’s rho tests. A significant analysis referred to a p-value of <0.05.
Results: The participants were 189 patients, consisting of 106 on gefitinib, 43 on erlotinib, and 40 on afatinib. The average PFS values in the gefitinib, erlotinib, and afatinib groups were 9.9±5.25, 8.77±4.53, and 12.83±7.02 months, respectively (p=0.016). Furthermore, there were no significant OS among the gefitinib (14.91±7.61 months), erlotinib (14.54±7.64 months), and afatinib group (15.51±8.13 months, p=0.867). There was a significant correlation between CEA levels and PFS (r=0.146; p=0.046) and between CEA levels and OS (r=0.223; p=0.004).
Conclusion: Although afatinib may prolong PFS compared with gefitinib and erlotinib, it did not significantly impact OS. Increased serum CEA levels before treatment significantly improved PFS and OS. However, elevated CEA levels are usually associated with a poor prognosis in NSCLC. |
| format | Article |
| id | doaj-art-86b76129c49f4b49bc1447a2bcf03cfd |
| institution | Kabale University |
| issn | 2407-0831 2621-8372 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Universitas Airlangga |
| record_format | Article |
| series | Jurnal Respirasi |
| spelling | doaj-art-86b76129c49f4b49bc1447a2bcf03cfd2025-08-20T03:25:59ZengUniversitas AirlanggaJurnal Respirasi2407-08312621-83722025-05-01112140146https://doi.org/10.20473/jr.v11-I.2.2025.140-146Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung CancerAgus Andreas Santoso0https://orcid.org/0009-0007-6789-962XSuryanti Dwi Pratiwi1https://orcid.org/0000-0002-4733-7837Yani Jane Sugiri2https://orcid.org/0000-0001-9221-6463Harun Al Rasyid3https://orcid.org/0000-0002-1345-9668Aditya Sri Listyoko4https://orcid.org/0000-0002-6811-7163Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.Doctoral Student, Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan.Introduction: Non-small cell lung cancer (NSCLC) was the primary cause of death in lung cancer. Tyrosine kinase inhibitors (TKIs) were one of the management options for NSCLC. Meanwhile, serum carcinoembryonic antigen (CEA) plays a crucial role in the diagnosis and prognosis of NSCLC patients. This study aimed to determine the effectiveness of epidermal growth factor receptor (EGFR)-TKI based on progression-free survival (PFS) and overall survival (OS) in NSCLC patients with common EGFR mutations. Methods: This retrospective cohort study used a total sampling method. The serum CEA level was measured before the initial treatment. Tyrosine kinase inhibitors therapy was monitored with PFS and OS. Statistical analysis for comparing prognosis in NSCLC among TKI groups used Kruskal-Wallis, analysis of variance (ANOVA), Mann-Whitney, and Spearman’s rho tests. A significant analysis referred to a p-value of <0.05. Results: The participants were 189 patients, consisting of 106 on gefitinib, 43 on erlotinib, and 40 on afatinib. The average PFS values in the gefitinib, erlotinib, and afatinib groups were 9.9±5.25, 8.77±4.53, and 12.83±7.02 months, respectively (p=0.016). Furthermore, there were no significant OS among the gefitinib (14.91±7.61 months), erlotinib (14.54±7.64 months), and afatinib group (15.51±8.13 months, p=0.867). There was a significant correlation between CEA levels and PFS (r=0.146; p=0.046) and between CEA levels and OS (r=0.223; p=0.004). Conclusion: Although afatinib may prolong PFS compared with gefitinib and erlotinib, it did not significantly impact OS. Increased serum CEA levels before treatment significantly improved PFS and OS. However, elevated CEA levels are usually associated with a poor prognosis in NSCLC.https://e-journal.unair.ac.id/JR/article/view/68755carcinoembryonic antigen (cea)egfr-tkinsclcoverall survival (os)progression-free survival (pfs) |
| spellingShingle | Agus Andreas Santoso Suryanti Dwi Pratiwi Yani Jane Sugiri Harun Al Rasyid Aditya Sri Listyoko Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer Jurnal Respirasi carcinoembryonic antigen (cea) egfr-tki nsclc overall survival (os) progression-free survival (pfs) |
| title | Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer |
| title_full | Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer |
| title_fullStr | Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer |
| title_full_unstemmed | Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer |
| title_short | Prognosis of Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer |
| title_sort | prognosis of tyrosine kinase inhibitor therapy for non small cell lung cancer |
| topic | carcinoembryonic antigen (cea) egfr-tki nsclc overall survival (os) progression-free survival (pfs) |
| url | https://e-journal.unair.ac.id/JR/article/view/68755 |
| work_keys_str_mv | AT agusandreassantoso prognosisoftyrosinekinaseinhibitortherapyfornonsmallcelllungcancer AT suryantidwipratiwi prognosisoftyrosinekinaseinhibitortherapyfornonsmallcelllungcancer AT yanijanesugiri prognosisoftyrosinekinaseinhibitortherapyfornonsmallcelllungcancer AT harunalrasyid prognosisoftyrosinekinaseinhibitortherapyfornonsmallcelllungcancer AT adityasrilistyoko prognosisoftyrosinekinaseinhibitortherapyfornonsmallcelllungcancer |